What is it about?
We discovered that Bruton's tyrosine kinase (BTK), the key molecule of B-cell antigen receptor signaling pathway is over expressed in orbital fibroblasts from GO, and BTK suppression by ibrutinib treatment suppressed of inflammatory cytokine production.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Ibrutinib is an orally bioavailable medication for B-cell malignancies and chronic graft-versus-host disease, and our result suggests possibility of ibrutinib as a potential treatment for GO.
Perspectives
Further studies are needed to evaluate the role of BTK and its inhibitors in inflammatory response in GO in clinical settings.
Hyun Young Park
Yonsei University
Read the Original
This page is a summary of: Therapeutic effect of ibrutinib, a selective Bruton’s tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves’ orbitopathy, PLoS ONE, December 2022, PLOS,
DOI: 10.1371/journal.pone.0279060.
You can read the full text:
Contributors
The following have contributed to this page
